Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lanza

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
The Journal of Heredity|August 27, 2002
The Charles River "hairless" rat mutation maps to chromosome 1: allelic with fuzzy and a likely orthologue of mouse frizzyK Ahearn, G Akkouris, P R Berry, et al.
Bioorganic & Medicinal Chemistry Letters|September 15, 2000
Substituted 2-aminopyridines as inhibitors of nitric oxide synthasesW K Hagmann, C G Caldwell, P Chen, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of ObesityHarry R Chobanian, Yan Guo, Ping Liu, et al.
Journal of Medicinal Chemistry|July 5, 2007
Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical usePing Liu, Linus S Lin, Terence G Hamill, et al.
Journal of Medicinal Chemistry|December 22, 2006
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesityLinus S Lin, Thomas J Lanza, James P Jewell, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 27, 2003
A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependenceLinda A Egger, Jin Cao, Christine McCallum, et al.
Bioorganic & Medicinal Chemistry Letters|February 13, 2007
Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonistsHelen E Armstrong, Amy Galka, Linus S Lin, et al.
Journal of Medicinal Chemistry|March 14, 1997
Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptidesC K Esser, R L Bugianesi, C G Caldwell, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2007
Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodentsTung M Fong, Xiao-Ming Guan, Donald J Marsh, et al.
Bioorganic & Medicinal Chemistry|April 13, 2012
The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerizationHarry R Chobanian, Yan Guo, Ping Liu, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The Journal of Heredity|August 27, 2002
The Charles River "hairless" rat mutation maps to chromosome 1: allelic with fuzzy and a likely orthologue of mouse frizzyK Ahearn, G Akkouris, P R Berry, et al.
Bioorganic & Medicinal Chemistry Letters|September 15, 2000
Substituted 2-aminopyridines as inhibitors of nitric oxide synthasesW K Hagmann, C G Caldwell, P Chen, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of ObesityHarry R Chobanian, Yan Guo, Ping Liu, et al.
Journal of Medicinal Chemistry|July 5, 2007
Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical usePing Liu, Linus S Lin, Terence G Hamill, et al.
Journal of Medicinal Chemistry|December 22, 2006
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesityLinus S Lin, Thomas J Lanza, James P Jewell, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 27, 2003
A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependenceLinda A Egger, Jin Cao, Christine McCallum, et al.
Bioorganic & Medicinal Chemistry Letters|February 13, 2007
Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonistsHelen E Armstrong, Amy Galka, Linus S Lin, et al.
Journal of Medicinal Chemistry|March 14, 1997
Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptidesC K Esser, R L Bugianesi, C G Caldwell, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2007
Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodentsTung M Fong, Xiao-Ming Guan, Donald J Marsh, et al.
Bioorganic & Medicinal Chemistry|April 13, 2012
The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerizationHarry R Chobanian, Yan Guo, Ping Liu, et al.
Pageof 4